Tracking every rollback, reversal, and overreach — and the path back to the America we know.
President Trump signed Executive Order 13948 on September 13, 2020, directing the Department of Health and Human Services to allow Medicare to pay no more for drugs than the lowest price paid in other developed countries. The order applied to a subset of Medicare Part B drugs. As of 2021, the rule was blocked by federal courts before implementation, preventing direct Medicare price changes for most drugs covered under the order.
On July 24, 2020, President Trump signed Executive Order 13937, directing the Department of Health and Human Services to establish a Most Favored Nation (MFN) model for Medicare drug pricing. The order required Medicare to pay no more for drugs than the lowest price paid in other developed nations. The rule was implemented in November 2020 but was blocked by federal courts before taking effect, and was subsequently rescinded by the Biden administration in 2021.
Executive Order 13939 was signed on July 24, 2020, directing the Department of Health and Human Services to issue a safe harbor rule removing anti-kickback protections for rebates in drug pricing negotiations. The order aimed to increase price transparency by allowing pharmaceutical manufacturers, pharmacy benefit managers, and health plans to negotiate rebates directly. The confirmed effect was that HHS issued a proposed rule in January 2021 to modify anti-kickback statute safe harbors, though implementation faced legal challenges and the rule's real-world impact on patient drug prices remained subject to ongoing litigation.
On July 24, 2020, President Trump signed Executive Order 13947 directing federal agencies to take steps to lower drug prices and increase price transparency. The order instructed the Department of Health and Human Services to allow states to import prescription drugs from Canada, permit Medicare to negotiate drug prices directly, and require drug manufacturers to disclose prices in direct-to-consumer advertising. Implementation faced legal challenges and delays; some provisions did not take effect during the Trump administration.
President Trump signed Executive Order 13890 on October 3, 2019, directing the Department of Health and Human Services to modify Medicare payment policies and drug pricing negotiations. The order instructed HHS to implement changes to Medicare payment rates for certain services and to advance drug price negotiations. The confirmed direct impact included modifications to Medicare reimbursement structures that affected healthcare provider payments and drug pricing mechanisms within the Medicare program.